Recent surge of mucormycosis in COVID-19 patients: clinicians’ perspective from systems genomics

Sudhir Mehta^{1, *}, Krishna Mohan Medicherla^{2, 4}, Ayyagari Subramanyam⁴, PB Kavi Kishor^{3, 4}, Prashanth Suravajhala^{2, 4, 5, *}

Affiliations
¹Department of General Medicine, SMS Medical College and Hospitals, Jaipur 302004, Rajasthan, India.
²Department of Biotechnology and Bioinformatics, Birla Institute of Scientific Research, Jaipur 302001, Rajasthan, India.
³Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research, Vadlamudi, Guntur 522213, Andhra Pradesh, India.
⁴Bioclues.org, India.
⁵Amrita School of Biotechnology, Amrita Vishwavidyapeetham, Clappana PO, Kerala, 690525, India.

Corresponding authors, emails: [email protected], [email protected]

Abstract
Mucormycosis has been largely associated with COVID-19 patients. With the growing number of cases, there is an immediate need to understand the treatment regimen for COVID-19 which could predispose to mucormycosis infection. The authors have highlighted the points from clinicians’ perspective.

Citation
Mehta S, Medicherla KM, Subramanyam A, Kishor PBK, Suravajhala P (2022) Recent surge of mucormycosis in COVID-19 patients: clinicians’ perspective from systems genomics. MycoAsia 2022/04. https://doi.org/10.59265/mycoasia.2022-04

Submission History
Received: 29.03.2022
Accepted: 06.05.2022
Published: 06.05.2022

Editorial Team
Handling Editor: Dr. Belle Damodara Shenoy
Reviewers: Dr. Primali Jayasekera, Dr. Prasanna Honnavara

Download PDF